Dr. Garyfalia Karponi
Clinically Actionable REarrangements
Background
Rearrangements (fusions) represent a category of genomic alterations that are attractive both as therapeutic targets and as diagnostic tools, due to their inherent expression exclusively in cancer tissues. In several cancers, rearrangements of specific genes are already pharmacologically targetable, while many of them are found in more than one type of cancer and are therefore characterized as tumor-agnostic.
What we offer
Testing for rearrangements (fusions) in 49 driver genes by NGS — see table below
In selected genes — ALK, FGFR2, NTRK1, NTRK2, NTRK3 and RET — the panel can also detect novel rearrangements, beyond the known literature-defined rearrangements, through Exon Tile Imbalance technology
In selected genes — AR, BRAF, BRCA1, EGFR, MET, NTRK1 and RELA — the panel can detect intragenic exon rearrangements and accurately predict exon skipping through RNA Exon Variant technology
| AKT1 | ERBB4 (HER4) | MET | NTRK3 | RET |
| AKT2 | ERG | MTAP | NUTM1 | ROS1 |
| AKT3 | ESR1 | MYB | PIK3CA | RSPO2 |
| ALK | ETV1 | MYBL1 | PIK3CB | RSPO3 |
| AR | ETV4 | NOTCH1 | PPARG | STAT6 |
| BRAF | ETV5 | NOTCH2 | PRKACA | TERT |
| BRCA1 | FGFR1 | NOTCH3 | PRKACB | TFE3 |
| CDKN2A | FGFR2 | NRG1 | RAF1 | TFEB |
| EGFR | FGFR3 | NTRK1 | RARA | YAP1 |
| ERBB2 (HER2) | MAP3K8 | NTRK2 | RELA |
Required sample: Formalin-fixed paraffin-embedded tissue (FFPE)
Turnaround time: 2 weeks
Please contact us for more information.
Garyfalia Karponi, MSc, PhD
Molecular Biologist-Geneticist
Chief Scientific Officer, Department of Molecular Diagnostics